


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華控康泰集團有限公司

Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

GRANT OF WAIVER FOR FURTHER DELAY IN DESPATCH OF CIRCULAR UNDER RULE 14.41(a) OF THE LISTING RULES

Reference is made to (i) the announcement of Kontafarma China Holdings Limited (the “**Company**”) dated 27 July 2026 in relation to renewal of lease for fitness and yoga centre (the “**Announcement**”); (ii) the announcement of the Company dated 17 August 2026 in relation to the delay in despatch of the Circular (the “**Delay Announcement**”) and (iii) the announcement of the Company dated 4 September 2026 in relation to the further delay in despatch of the Circular (the “**Further Delay Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement, the Delay Announcement and the Further Delay Announcement.

As disclosed in the Delay Announcement, the Circular, containing, among other things, (i) information on the New Lease; and (ii) other information required under the Listing Rules, will be despatched to the Shareholders on or before 4 September 2026. It was further disclosed in the Further Delay Announcement that the Company had applied to the Stock Exchange for a second waiver from strict compliance with the requirements of Rule 14.41(a) of the Listing Rules and pending approval from the Stock Exchange as additional time is required for the Company to finalise the information set out in the Circular.

On 23 September 2026, the Stock Exchange granted the Second Waiver on the condition that the Circular will be despatched on or before 24 September 2026. The Second Waiver applies to this case only and the Stock Exchange may withdraw or change the Second Waiver if the Company's situation changes.

By order of the Board of
Kontafarma China Holdings Limited
Wang Limin
Chairman

Hong Kong, 24 September 2026

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Limin (Chairman), Mr. Li Qingshan (President), Mr. Ge Shouwen (Vice President), and Ms. Guo Zixiu (Financial Controller); and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.